Ensoma raised $53 million to develop in vivo genomic medicines that deliver gene modification technologies directly to blood and immune cells, offering potentially curative treatments in a single injection for rare diseases.
Ensoma raised $53 million to develop in vivo genomic medicines that deliver gene modification technologies directly to blood and immune cells, offering potentially curative treatments in a single injection for rare diseases.
